Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance

Iovance Biotherapeutics Inc. Common StockTrade
Vanguard Total International Stock Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Iovance Biotherapeutics Inc. Common Stock vs Vanguard Total International Stock Index Fund ETF — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.45 (market cap $6.04B), while Vanguard Total International Stock Index Fund ETF trades at $84.73 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 110.2× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Vanguard Total International Stock Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Vanguard Total International Stock Index Fund ETF for 55 Days on average.

IOVAVXUS
Market Cap
$6.04B$665.70B
Volume
14,805,9934,864,744
Sector
HealthSector/Thematic
52-Week High
$14.82$88.41
52-Week Low
$1.81$72.17
Typical Hold Time
0 Days55 Days
Enterprise Value
$5.97B—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Iovance Biotherapeutics Inc. Common Stock

No Aura AI signal available yet.

Vanguard Total International Stock Index Fund ETF

VXUS trades at $84.78, down 1.19% with a bearish technical signal from moving averages. The ETF provides broad international stock exposure outside the U.S., with institutional buying interest noted in recent SEC filings. Technical indicators show neutral oscillators but bearish momentum signals from ADX readings.

The fund offers diversification benefits as a core international holding, though recent performance faces headwinds. Key risks include currency fluctuations and emerging market volatility. Long-term outlook remains positive for global equity exposure, supported by Vanguard's low-cost structure and comprehensive market coverage.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IOVA
100% Buy0% Sell
Avg holding period · 0 Days
VXUS
81% Buy19% Sell
Avg holding period · 55 Days

About Iovance Biotherapeutics Inc. Common Stock

Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.

Read more on IOVA →

About Vanguard Total International Stock Index Fund ETF

VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.

Read more on VXUS →